201 related articles for article (PubMed ID: 31700186)
21. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
Litviakov N; Tsyganov M; Larionova I; Ibragimova M; Deryusheva I; Kazantseva P; Slonimskaya E; Frolova I; Choinzonov E; Cherdyntseva N; Kzhyshkowska J
Cancer Chemother Pharmacol; 2018 Jul; 82(1):99-109. PubMed ID: 29728799
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
23. RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point.
Lee JW; Kim DM; Jang JW; Park TG; Song SH; Lee YS; Chi XZ; Park IY; Hyun JW; Ito Y; Bae SC
Nat Commun; 2019 Apr; 10(1):1897. PubMed ID: 31015486
[TBL] [Abstract][Full Text] [Related]
24. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
26. Distinguishing between biochemical and cellular function: Are there peptide signatures for cellular function of proteins?
Jain S; Bhattacharyya K; Bakshi R; Narang A; Brahmachari V
Proteins; 2017 Apr; 85(4):682-693. PubMed ID: 28097693
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
28. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Jasra S; Anampa J
Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
[TBL] [Abstract][Full Text] [Related]
29. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
30. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair.
Chen J; Liu JY; Dong ZZ; Zou T; Wang Z; Shen Y; Zhuo W; Li XP; Xiao D; Liu HT; Chen X; Zhou HH; Liu ZQ; Zhang JT; Yin JY
Biochem Pharmacol; 2021 Aug; 190():114616. PubMed ID: 34022189
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
34. ARID1A regulates R-loop associated DNA replication stress.
Tsai S; Fournier LA; Chang EY; Wells JP; Minaker SW; Zhu YD; Wang AY; Wang Y; Huntsman DG; Stirling PC
PLoS Genet; 2021 Apr; 17(4):e1009238. PubMed ID: 33826602
[TBL] [Abstract][Full Text] [Related]
35. Anthracyclines in early-stage breast cancer: is it the end of an era?
Robson D; Verma S
Oncologist; 2009 Oct; 14(10):950-8. PubMed ID: 19561291
[TBL] [Abstract][Full Text] [Related]
36. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
37. Promoter bivalency favors an open chromatin architecture in embryonic stem cells.
Mas G; Blanco E; Ballaré C; Sansó M; Spill YG; Hu D; Aoi Y; Le Dily F; Shilatifard A; Marti-Renom MA; Di Croce L
Nat Genet; 2018 Oct; 50(10):1452-1462. PubMed ID: 30224650
[TBL] [Abstract][Full Text] [Related]
38. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
[TBL] [Abstract][Full Text] [Related]
39. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines.
Jeschke J; O'Hagan HM; Zhang W; Vatapalli R; Calmon MF; Danilova L; Nelkenbrecher C; Van Neste L; Bijsmans IT; Van Engeland M; Gabrielson E; Schuebel KE; Winterpacht A; Baylin SB; Herman JG; Ahuja N
Clin Cancer Res; 2013 Jun; 19(12):3201-11. PubMed ID: 23630167
[TBL] [Abstract][Full Text] [Related]
40. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
